In addition, several immune checkpoint genes were also differentially expressed in the high and low risk group of lung cancer patients in the cohorts, the high risk group has the higher expression of CD276 in both TCGA and GSE72094 LUAD cohorts, while the low risk group has the higher expression of CD27, CD40LG, or NCR3 in both cohorts, indicating the possible use of blockers targeting different immune checkpoint genes for different risk groups. This evidence concerns the gene CD276 and lung carcinoma.